Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide is an experimental small molecule compound belonging to the diphenylether class. It contains a pyridopyrimidine core with two amino groups and a phenoxybenzamide moiety. The compound has been referenced in structural biology as ligand 3B9 but does not have an established clinical indication or approved use. Its mechanism of action is not explicitly described in public databases; however, related pyridopyrimidine derivatives are known to act as antifolates and may inhibit dihydrofolate reductase (DHFR), interfering with folate metabolism and DNA synthesis—a mechanism common to drugs like methotrexate and aminopterin[1][5]. No clinical trials or regulatory approvals are reported for this molecule.
- Other names
- N-(2-{2,4-diaminopyrido[2,3-d]pyrimidin-7-yl}-2-methylpropyl)-4-phenoxybenzamideBenzamide, N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxy-
02
Targets
DHFR (Dihydrofolate reductase)DHFR-TS (Bifunctional dihydrofolate reductase-thymidylate synthase)
Beyond the preview
Go deeper on N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide.